Rybrevant 350 mg Concentrate for solution for infusion
PDF Leaflet Revision Date: 29 October 2025
Clinical Summary
Quick overview from the medicine insert
Indication
First-line treatment of advanced/metastatic NSCLC with specific EGFR mutations.
Dosage (summary)
Administered every 3 weeks or every 2 weeks based on combination or monotherapy.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Risk of fetal harm; avoid breastfeeding during treatment and for 3 months after.
Key Drug Interactions
- Avoid live vaccines
Contraindications
- Hypersensitivity to amivantamab
Common side effects
- Rash
- Infusion-related reactions
- Nail toxicity
- Fatigue
- Nausea
Counselling Points
- Use effective contraception during treatment
- Monitor for skin reactions
- Avoid sun exposure
Serious warnings
- Infusion-related reactions
- Interstitial lung disease
Important Disclaimer
The Rybrevant 350 mg Concentrate for solution for infusion professional information leaflet below is the property of Janssen Pharmaceutica and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
